Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials

References

• Brown RH, Al-Chalabi A, Longo DL. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162‐172.
   Web of Science ®Google Scholar
• Johnston CA, Stanton BR, Turner MR, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253(12):1642–1643.
   PubMed Web of Science ®Google Scholar
• Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology. 2003;22(4):217–228.
   PubMed Web of Science ®Google Scholar
• Ravits J, Paul P, Jorg C. Focality of upper and lowermotor neuron degeneration at the clinical onset of ALS. Neurology. 2007;68(19):1571–1575.
   PubMed Web of Science ®Google Scholar
• Chiò A, Calvo A, Moglia C, et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740–746.
   PubMed Web of Science ®Google Scholar
• Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12(3):310–322.
   PubMed Web of Science ®Google Scholar
• Lillo P, Matamala JM, Valenzuela D, et al. [Overlapping features of frontotemporal dementia and amyotrophiclateral sclerosis]. Rev Med Chil. 2014;142(7):867–879.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–133.
   PubMed Web of Science ®Google Scholar
• Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–611.
   PubMed Web of Science ®Google Scholar
• Hardiman O, Traynor BJ, Corr B, et al. Models of care for motor neuron disease: setting standards. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(4):182–185.
   PubMed Web of Science ®Google Scholar
• Chio A, Bottacchi E, Buffa C, et al. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77(8):948–950.
   PubMed Web of Science ®Google Scholar
• Albert SM, Whitaker A, Rabkin JG, et al. Medical and supportive care among people with ALS in the months before death or tracheostomy. J Pain Symptom Manage. 2009;38(4):546–553.
   PubMed Web of Science ®Google Scholar
• Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry. 2003;74(Suppl 4):iv32–iv47.
   PubMedGoogle Scholar
• Amato AA, Russel JA. Neuromuscular Disorders. New York (NY): McGraw-Hill Education; 2016.
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis ALS/riluzole study group. N Engl J Med. 1994;330(9):585–591.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis amyotrophic lateral sclerosis/riluzole study group II. Lancet. 1996;347(9013):1425–1431.
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Traynor BJ, Cudkowicz ME. Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007;12(2):229–252.
   PubMed Web of Science ®Google Scholar
• Fujisawa A, Yamamoto Y. Edaravone, a potent free radical scavenger, reactswith peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 2016;21(3):98–103.
   PubMed Web of Science ®Google Scholar
• Beal MF, Ferrante RJ, Browne SE, et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateralsclerosis. Ann Neurol. 1997;42(4):644–654.
   PubMed Web of Science ®Google Scholar
• Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;4:241–245.
   Google Scholar
• Abe K, Itoyama Y, Sobue G, et al. Edaravone ALS Study Group Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7–8):610–617.
   PubMed Web of Science ®Google Scholar
• Abe K, Aoki M, Tsuji S, Writing Group. Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–512.
   PubMed Web of Science ®Google Scholar
• Fortuna A, Gizzi M, Bello L, et al. Edaravone Study Group. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. J Neurol Sci. 2019;404:47–51.
   PubMed Web of Science ®Google Scholar
• Park JM, Kim SY, Park D, et al. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci. 2020;41(1):119–123.
   PubMed Web of Science ®Google Scholar
• Jackson C, Heiman-Patterson T, Kittrell P, et al. Radicava (edaravone) for amyotrophic lateral sclerosis: uSexperience at 1 year after launch. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7–8):605–610.
   PubMed Web of Science ®Google Scholar
• Smith R, Pioro E, Myers K, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics. 2017;14(3):762–772.
   PubMed Web of Science ®Google Scholar
• Chiò A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–130.
   PubMed Web of Science ®Google Scholar
• Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68(13):1002–1007.
   PubMed Web of Science ®Google Scholar
• Arthur KC, Calvo A, Price TR, et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7(1):12408.
   PubMedGoogle Scholar
• Oh J, An JW, Oh SI, et al. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3–4):202–208.
   PubMed Web of Science ®Google Scholar
• Clark JE, Brennan A, Ramesh TM, et al. Novel trends in orphan market drug discovery: amyotrophic lateral sclerosis as a case study. Front Biosci. 2002;7:c83–96.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.
   PubMed Web of Science ®Google Scholar
• Thonhoff JR, Beers DR, Zhao W, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e465.
   PubMed Web of Science ®Google Scholar
• Lanuza MA, Just-Borràs L, Hurtado E, et al. The impact of kinases in amyotrophic lateral sclerosis at the neuromuscular synapse: insights into BDNF/TrkB and PKC signaling. Cells. 2019;8(12):12.
   Web of Science ®Google Scholar
• Mathis S, Goizet C, Soulages A, et al. Genetics of amyotrophic lateral sclerosis: a review. J Neurol Sci. 2019;399:217–226.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81(12):1324–1326.
   PubMed Web of Science ®Google Scholar
• Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2013;17(1):17–23.
   PubMed Web of Science ®Google Scholar
• Rutherford NJ, Zhang YJ, Baker M, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4(9):e1000193.
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobágyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208–1211. 27.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205–1208.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467–473.
   PubMed Web of Science ®Google Scholar
• Johnson JO, Pioro EP, Boehringer A, et al. Mutations in the matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014;17(5):664–666.
   PubMed Web of Science ®Google Scholar
• Ticozzi N, Vance C, Leclerc AL, et al. Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amytrophic laterl scleroris. Am J Med Genet B Neuropsychiatric Genet. 2011;156B(3):285–290.
   PubMedGoogle Scholar
• Ito D, Hatano M, Suzuki N. RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration. Sci Transl Med. 2017;9(415):415.
   Web of Science ®Google Scholar
• Lee YB, Chen HJ, Peres JN, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5(5):1178–1186.
   PubMed Web of Science ®Google Scholar
• Mori K, Arzberger T, Grässer FA, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126(6):881–893.
   PubMed Web of Science ®Google Scholar
• Cooper-Knock J, Shaw PJ, Kirby J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 2014;127(3):333–345.
   PubMed Web of Science ®Google Scholar
• Prudencio M, Belzil VV, Batra R, et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci. 2015;18(8):1175–1182.
   PubMed Web of Science ®Google Scholar
• Takeda T, Kitagawa K, Arai K. Phenotypic variability and its pathological basis in amyotrophic lateral sclerosis. Neuropathology. 2020;40(1):40–56.
   PubMed Web of Science ®Google Scholar
• Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364(6435):362.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427–434.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Neuropathological stageing of alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Del Tredici K, Lee VM, et al. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015;16(2):109–120.
   PubMed Web of Science ®Google Scholar
• Menzies FM, Fleming A, Caricasole A, et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron. 2017;93(5):1015–1034.
   PubMed Web of Science ®Google Scholar
• Almeida S, Gao FB. Lost & found: C9ORF72 and the autophagy pathway in ALS/FTD. Embo J. 2016;35(12):1251–1253.
   PubMed Web of Science ®Google Scholar
• Soo KY, Halloran M, Sundaramoorthy V, et al. Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS. Acta Neuropathol. 2015;130(5):679–697.
   PubMed Web of Science ®Google Scholar
• Stoica R, De Vos KJ, Paillusson S, et al. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat Commun. 2014;5(1):3996.
   PubMedGoogle Scholar
• Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295):223–226.
   PubMed Web of Science ®Google Scholar
• Teyssou E, Takeda T, Lebon V, et al. Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol. 2013;125(4):511–522.
   PubMed Web of Science ®Google Scholar
• Matsumoto G, Shimogori T, Hattori N, et al. TBK1 controls autophagosomal engulfment of polyubiquitinated mitochondria through p62/SQSTM1 phosphorylation. Hum Mol Genet. 2015;24(15):4429–4442.
   PubMed Web of Science ®Google Scholar
• Ji YJ, Ugolino J, Brady NR, et al. Systemic deregulation of autophagy upon loss of ALS- and FTD-linked C9orf72. Autophagy. 2017;13(7):1254–1255..
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Neurodegenerative diseases and prions. N Engl J Med. 2001;344(20):1516–1526.
   PubMed Web of Science ®Google Scholar
• Grad LI, Fernando SM, Cashman NR. From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis. Neurobiol Dis. 2015;77:257–265.
   PubMed Web of Science ®Google Scholar
• McAlary L, Plotkin SS, Yerbury JJ, et al. Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:262.
   PubMed Web of Science ®Google Scholar
• Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. Biochem J. 2017;474(8):1417–1438.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Dewil M, Robberecht W, et al. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis. 2005;2(3–4):147–159.
   PubMed Web of Science ®Google Scholar
• Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther. 2011;17(1):4–31.
   PubMed Web of Science ®Google Scholar
• Kleine BU, Stegeman DF, Schelhaas HJ, et al. Firing pattern of fasciculations in ALS: evidence for axonal and neuronal origin. Neurology. 2008;70(5):353–359.
   PubMed Web of Science ®Google Scholar
• Mills KR. Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign fasciculation syndrome. Brain. 2010;133(11):3458–3469.
   PubMedGoogle Scholar
• Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol. 1988;24(3):446–449.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration. 1995;4(2):209–216.
   PubMedGoogle Scholar
• Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci. 2002;193(2):73–78.
   PubMed Web of Science ®Google Scholar
• Milanese M, Zappettini S, Onofri F, et al. Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2011;116(6):1028–1042.
   PubMed Web of Science ®Google Scholar
• Fray AE, Ince PG, Banner SJ, et al. The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study. Eur J Neurosci. 1998;10(8):2481–2489.
   PubMed Web of Science ®Google Scholar
• Sun H, Kawahara Y, Ito K, et al. Slow and selective death of spinal motor neurons in vivo by intrathecal infusion of kainic acid: implications for AMPA receptor-mediated excitotoxicity in ALS. J Neurochem. 2006;98(3):782–791.
   PubMed Web of Science ®Google Scholar
• Vucic S, Kiernan MC. Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. Handb Clin Neurol. 2013;116:561–575.
   PubMedGoogle Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–795.
   PubMed Web of Science ®Google Scholar
• Niedzielska E, Smaga I, Gawlik M, et al. Oxidative stress in neurodegenerative diseases. Mol Neurobiol. 2016;53(6):4094–4125.
   PubMed Web of Science ®Google Scholar
• Clobey JN, Fiorello ML, Bailey DM. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018;15:490–503.
   PubMed Web of Science ®Google Scholar
• Jami MS, Salehi-Najafabadi Z, Ahmadinejad F, et al. Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress. Neurochem Int. 2015;90:134–141.
   PubMed Web of Science ®Google Scholar
• Sekizawa T, Openshaw H, Ohbo K, et al. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci. 1998;154(2):194–199.
   PubMed Web of Science ®Google Scholar
• Almer G, Guégan C, Teismann P, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol. 2001;49(2):176–185.
   PubMed Web of Science ®Google Scholar
• Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601–609.
   PubMed Web of Science ®Google Scholar
• Corcia P, Tauber C, Vercoullie J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7(12):e52941.
   PubMed Web of Science ®Google Scholar
• Henkel JS, Beers DR, Wen S, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64–79.
   PubMed Web of Science ®Google Scholar
• Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013;8(4):888–899.
   PubMed Web of Science ®Google Scholar
• Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–487.
   PubMed Web of Science ®Google Scholar
• Hooten KG, Beers DR, Zhao W, et al. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):364–375.
   PubMed Web of Science ®Google Scholar
• Buchan JR, Kolaitis RM, Taylor JP, et al. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell. 2013;153(7):1461–1474.
   PubMed Web of Science ®Google Scholar
• Shi CS, Shenderov K, Huang NN, et al. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol. 2012;13(3):255–263.
   PubMed Web of Science ®Google Scholar
• Lipton JO, Sahin M. The neurology of mTOR. Neuron. 2014;84(2):275–291.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Majumder S, Deng JJ, et al. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem. 2009;284(40):27416–27424.
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38(6):411–419.
   PubMed Web of Science ®Google Scholar
• Crippa V, D’Agostino VG, Cristofani R, et al. Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. Sci Rep. 2016;6(1):22827.
   PubMed Web of Science ®Google Scholar
• Cadwell K. Crosstalk between autophagy and inflammatory signalling pathways: balancing defence and homeostasis. Nat Rev Immunol. 2016;16(11):661–675.
   PubMed Web of Science ®Google Scholar
• Khasnavis S, Jana A, Roy A, et al. Suppression of nuclear factor-κB activation and inflammation in microglia by physically modified saline. J Biol Chem. 2012;287(35):29529–29542.
   PubMed Web of Science ®Google Scholar
• Mondal S, Martinson JA, Ghosh S, et al. Protection of Tregs, suppression of Th1 and Th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline. PloS One. 2012;7(12):e51869.
   PubMed Web of Science ®Google Scholar
• Modi KK, Jana A, Ghosh S, et al. A physically-modified saline suppresses neuronal apoptosis, attenuates tau phosphorylation and protects memory in an animal model of Alzheimer’s disease. PloS One. 2014;9(8):e103606.
   PubMed Web of Science ®Google Scholar
• Rao VT, Khan D, Jones RG, et al. Potential benefit of the charge-stabilized nanostructure saline rns60 for myelin maintenance and repair. Sci Rep. 2016;6(1):30020.
   PubMedGoogle Scholar
• Vallarola A, Sironi F, Tortarolo M, et al. RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. J Neuroinflammation. 2018;15(1):65.
   PubMedGoogle Scholar
• Paganoni S, Alshikho MJ, Luppino S, et al. A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle Nerve. 2019;59(3):303–308.
   PubMed Web of Science ®Google Scholar
• Vigletta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4þCD25þ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199(7):971–979.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising Foxp3-expressing CD25þCD4þ regulatory T cells in immunological tolerance to self and nonself. Nat Immunol. 2005;6(4):345–352.
   PubMed Web of Science ®Google Scholar
• Sheean RK, McKay FC, Cretney E, et al. Association of regulatory t-cell expansion with progression of amyotrophic lateral sclerosis: A study of humans and a transgenic mouse model. JAMA Neurol. 2018;75(6):681–689.
   PubMed Web of Science ®Google Scholar
• Beers DR, Henkel JS, Zhao W, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134(Pt 5):1293–1314.
   PubMedGoogle Scholar
• Zondler L, Müller K, Khalaji S, et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 2016;132(3):1–21.
   Web of Science ®Google Scholar
• Zondler L, Feiler MS, Freischmidt A, et al. Impaired activation of ALS monocytes by exosomes. Immunol Cell Biol. 2017;95(2):207–214.
   PubMed Web of Science ®Google Scholar
• Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39(2):147–157.
   PubMed Web of Science ®Google Scholar
• Desnuelle C, Dib M, Garrel C, et al. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(1):9–18.
   PubMed Web of Science ®Google Scholar
• Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna). 2005;112(5):649–660.
   PubMed Web of Science ®Google Scholar
• Orrell RW, Lane RJM, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Sys Rev 2007;1:CD002829.
   Google Scholar
• Wang Y, Qin ZH. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis. 2010;15(11):1382–1402.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Weisskopf MG, O’Reilly EJ, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol. 2005;57(1):104–110.
   PubMed Web of Science ®Google Scholar
• Michal Freedman D, Kuncl RW, Weinstein SJ, et al. Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(4):246–251.
   PubMed Web of Science ®Google Scholar
• Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78(11):6858–6862.
   PubMed Web of Science ®Google Scholar
• Bowman GL, Shannon J, Frei B, et al. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010;19(4):1331–1336.
   PubMed Web of Science ®Google Scholar
• Chamorro A, Dirnagl U, Urra X, et al. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 2016;15(8):869–881.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Nicholson K, Chan J, et al. Urate levels predict survival in amyotrophic lateral sclerosis: analysis of the expanded pooled resource open-access ALS clinical trials database. Muscle Nerve. 2018;57(3):430–434.
   PubMed Web of Science ®Google Scholar
• Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in parkinson disease. Exp Neurol. 2017;298:210–224.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y. Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite. J Clin Biochem Nutr. 2017;60(1):49–54.
   PubMed Web of Science ®Google Scholar
• Nagase M, Yamamoto Y, Miyazaki Y, et al. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21(3):104–112.
   PubMed Web of Science ®Google Scholar
• O’Reilly ÉJ, Liu D, Johns DR, et al. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1–2):120–125.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Zhang M, Quiroz Zarate A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012;259(9):1923–1928.
   PubMed Web of Science ®Google Scholar
• Atassi N, Berry J, Shui A, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719–1725.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang Q, Ke Y, et al. Serum uric acid levels in patients with amyotrophic lateral sclerosis: a meta-analysis. Sci Rep. 2018;8(1):1100.
   PubMedGoogle Scholar
• Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460–1468.
   PubMed Web of Science ®Google Scholar
• Simon KC, Eberly S, Gao X, et al. Mendelian randomization of serum urate and Parkinson disease progression. Ann Neurol. 2014;76(6):862–868.
   PubMed Web of Science ®Google Scholar
• Adachi Y, Sato N, Saito Y, et al. Usefulness of SWI for the detection of iron in the motor cortex in amyotrophic lateral sclerosis. J Neuroimaging. 2015;25(3):443–451.
   PubMed Web of Science ®Google Scholar
• Kwan JY, Jeong SY, Van Gelderen P, et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS One. 2012;7(4):e35241.
   PubMed Web of Science ®Google Scholar
• Lu A, Rajanala M, Mikkilineni S, et al. The 5ʹ-untranslated region of the C9orf72 mRNA exhibits a phylogenetic alignment to the cis-aconitase iron-responsive element; novel therapies for amytrophic lateral sclerosis. Neurosci Med. 2016;7(1):15–26.
   Google Scholar
• Veyrat-Durebex C, Corcia P, Mucha A, et al. Iron metabolism disturbance in a French cohort of ALS patients. Biomed Res Int. 2014;2014:485723.
   PubMed Web of Science ®Google Scholar
• Williams JR, Trias E, Beilby PR, et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol Dis. 2016;89:1–9.
   PubMed Web of Science ®Google Scholar
• Soon CP, Donnelly PS, Turner BJ, et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem. 2011;286(51):44035–44044.
   PubMed Web of Science ®Google Scholar
• Son M, Puttaparthi K, Kawamata H, et al. Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology. Proc Natl Acad Sci USA. 2007;104(14):6072–6077.
   PubMed Web of Science ®Google Scholar
• Donnelly PS, Liddell JR, Lim S, et al. An impaired mitochondrial electron transport chain increases retention of the hypoxia imagin agent diacetylbis(4methylthiosemicarbazonato)copperII. Proc Natl Acad Sci USA. 2012;109(1):47–52.
   PubMed Web of Science ®Google Scholar
• Yoshii Y, Yoneda M, Ikawa M, et al. Radiolabeled cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less rho0 cells and cybrids carrying MELAS mitochondrial DNA mutation. Nucl Med Biol. 2012;39(2):177–185.
   PubMed Web of Science ®Google Scholar
• Akamatsu M, Yamashita T, Hirose N, et al. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep. 2016;6(1):28649.
   PubMedGoogle Scholar
• Li L, Sengupta A, Haque N, et al. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004;566(1–3):261–269.
   PubMed Web of Science ®Google Scholar
• Levine TD, Bowser R, Hank N, et al. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler. 2010;11(6):514–519.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Pinto S, Costa J, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(5):456–460.
   PubMed Web of Science ®Google Scholar
• Smethurst P, Risse E, Tyzack GE, et al. Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain. 2020;143(2):430–440.
   PubMed Web of Science ®Google Scholar
• Solling C. Organ-protective and immunomodulatory effects of erythropoietin - an update on recent clinical trials. Basic Clin Pharmacol Toxicol. 2012;110(2):113–121.
   PubMed Web of Science ®Google Scholar
• Lauria G, Dalla Bella E, Antonini G, et al. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. J Neurol Neurosurg Psychiatry. 2015;86(8):879–886.
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Zhou Y, Jana M, et al. Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J Immunol. 2003;170(7):3874–3882.
   PubMed Web of Science ®Google Scholar
• Chang J, Hsieh-Li H, Jong Y, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA. 2001;98(17):980813.
   Web of Science ®Google Scholar
• Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J Neurosci. 2003;23(28):9418–9427.
   PubMed Web of Science ®Google Scholar
• Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93(5):1087–1098.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10(2):99–106.
   PubMed Web of Science ®Google Scholar
• Amaral JD, Viana RJ, Ramalho RM, et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50(9):1721–1734.
   PubMed Web of Science ®Google Scholar
• Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999;159(22):2647–2658.
   PubMed Web of Science ®Google Scholar
• Elia AE, Lalli S, Monsurrò MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45–52.
   PubMed Web of Science ®Google Scholar
• Murch SJ, Cox PA, Banack SA, et al. Occurrence of beta-methylamino-L-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand. 2004a;110(4):267–269.
   PubMed Web of Science ®Google Scholar
• Murch SJ, Cox PA, Banack SA. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci. 2004b;101(33):12228–12231.
   PubMed Web of Science ®Google Scholar
• Rodgers K, Dunlop R. The cyanobacteria-derived BMAA can be incorporated into cell proteins and could thus be an environmental trigger for ALS and other neurological diseases associated with protein misfolding. Amyotroph Lateral Scler. 2011;12(Suppl 1):22.
   Google Scholar
• Dunlop RA, Cox PA, Banack SA, et al. The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation. PLoS One. 2013;8(9):e75376.
   PubMed Web of Science ®Google Scholar
• Dunlop RA, Powell JT, Metcalf JS, et al. L-serine-mediated neuroprotection includes the upregulation of the er stress chaperone protein disulfide isomerase (PDI). Neurotox Res. 2018;33(1):113–122.
   PubMed Web of Science ®Google Scholar
• Bradley WG, Miller RX, Levine TD, et al. Studies of environmental risk factors in amyotrophic lateral sclerosis (ALS) and a phase i clinical trial of l-serine. Neurotox Res. 2018;33(1):192–198.
   PubMed Web of Science ®Google Scholar
• Tueth MJ, Cheong JA. Clinical uses of pimozide. South Med J. 1993;86(3):344–349.
   PubMed Web of Science ®Google Scholar
• Bancila M, Copin JC, Daali Y, et al. Two structurally different T-type Ca2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats. Fundam Clin Pharmacol. 2010;25(4):469–478.
   PubMed Web of Science ®Google Scholar
• Szczudlik A, Tomik B, Słowik A, et al. [Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes]. Neurol Neurochir Pol. 1998;32(4):821–829.
   PubMedGoogle Scholar
• Patten SA, Aggad D, Martinez J, et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight. 2017;2(22):22.
   Web of Science ®Google Scholar
• Pozzi S, Thammisetty SS, Julien JP. Chronic administration of pimozide fails to attenuate motor and pathological deficits in two mouse models of amyotrophic lateral sclerosis. Neurotherapeutics. 2018;15(3):715–727.
   PubMed Web of Science ®Google Scholar
• Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008;105(6):2052–2057.
   PubMed Web of Science ®Google Scholar
• Leng Y, Liang MH, Ren M, et al. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci. 2008;28(10):2576–2588.
   PubMed Web of Science ®Google Scholar
• Feng HL, Leng Y, Ma CH, et al. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience. 2008;155(3):567–572.
   PubMed Web of Science ®Google Scholar
• Boll MC, Bayliss L, Vargas-Cañas S, et al. Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2014;340(1–2):103–108.
   PubMed Web of Science ®Google Scholar
• Koch J-C, Tatenhorst L, Roser AE, et al. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther. 2018;189(C):1–21.
   PubMedGoogle Scholar
• Komagome RR, Kimura KK, Saito MM. Postnatal changes in Rho and Rhorelated proteins in the mouse brain. Jpn J Vet Res. 2000;47(3–4):127–133.
   PubMed Web of Science ®Google Scholar
• Conti A, Riva N, Pesca M, et al. Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients. Biochim Biophys Acta. 2014;1842(1):99–106..
   PubMed Web of Science ®Google Scholar
• Tönges L, Koch JC, Bähr M, et al. ROCKing regeneration: rho kinase inhibition as molecular target for neurorestoration. Front Mol Neurosci. 2010;4:39.
   Web of Science ®Google Scholar
• Takata M, Tanaka H, Kimura M, et al. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. 2013;170(2):341–351.
   PubMed Web of Science ®Google Scholar
• Younger DS, Rowland LP, Latov N, et al. Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol. 1991;29(1):78–86.
   PubMed Web of Science ®Google Scholar
• McCormick AL, Brown RH, Cudkowicz ME, et al. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology. 2008;70(4):278–283.
   PubMed Web of Science ®Google Scholar
• MacGowan DJL, Scelsa SN, Imperato TE, et al. A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. Neurology. 2007;68(22):1944–1946.
   PubMed Web of Science ®Google Scholar
• Gold J, Rowe DB, Kiernan MC, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7–8):595–604.
   PubMed Web of Science ®Google Scholar
• Kaneb HM, Sharp PS, Rahmani-Kondori N, et al. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One. 2011;6(9):e24189.
   PubMed Web of Science ®Google Scholar
• Beyreuther B, Callizot N, Stöhr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol. 2006;539(1–2):6470.
   Web of Science ®Google Scholar
• Stöhr T, Krause E, Selve N. Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain. 2006;10(3):241249.
   Web of Science ®Google Scholar
• Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113(20):2462–2472.
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92(Suppl 4)):iv6–iv14.
   PubMedGoogle Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50(1):259–293.
   PubMedGoogle Scholar
• Cappella M, Ciotti C, Cohen-Tannoudji M, et al. Gene therapy for ALS-A perspective. Int J Mol Sci. 2019;20:18.
   Google Scholar
• Smith RA. Antisense oligonucleotide therapy for neurodegenerative disease. J Clinic Investig. 2006;116(8):2290–2296.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435–442.
   PubMed Web of Science ®Google Scholar
• Abati E, Bresolin N, Comi G, et al. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS). Expert Opin Ther Targets. 2020;24(4):295–310..
   PubMed Web of Science ®Google Scholar
• Trias E, Ibarburu S, Barreto‐Núñez R, et al. Post‐paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation. 2016;13(1):177.
   PubMedGoogle Scholar
• Mora JS, Genge A, Chio A, et al. Masitinib as an add‐on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;1‐10.
   Web of Science ®Google Scholar
• European Medicines Agency. Amsterdam: assessment report; [2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_
   Google Scholar
• Cho Y, Crichlow GV, Vermeire JJ, et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA. 2010;107(25):11313–11318.
   PubMed Web of Science ®Google Scholar
• Ruiz-Pérez D, Benito J, Polo G. The effects of the toll-like receptor 4 antagonist, ibudilast, on sevoflurane’s minimum alveolar concentration and the delayed remifentanil-induced increase in the minimum alveolar concentration in rats. Anesth Analg. 2016;122(5):1370–1376.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Coffey CS, Conwit R, et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018;379(9):846–855.
   Web of Science ®Google Scholar
• Brooks B, Bravver E, Sanjak M, et al. Adaptive design single center phosphodiesterase type 4 (PDE4) inhibitor-ibudilast (MN-166-ALS-1201) Phase 1b/2a clinical trial double - blind (DB) with open label extension (OLE) [NCT02238626] for Amyotrophic Lateral Sclerosis (ALS) patients not requiring non-invasive ventilation (no NIV) up to 5 years (Early Cohort-EC) and requiring non-invasive ventilation (NIV) up to 10 years (Advanced NIV Cohort-ANC) from disease onset e report of clinical trial DB, OLE and post-treatment cessation epochs e per-protocol (PP) treatment completion associated with improved survival and post treatment cessation loss of muscle strength. 69th Annual meeting of American Academy of Neurology; 2017 Apr 22-28; Boston, MA.
   Google Scholar
• Haikala H, Levijoki J, Lindén IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol. 1995;27(10):2155–2165.
   PubMed Web of Science ®Google Scholar
• van Hees HWH, Andrade Acuña G, Linkels M, et al. Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure. Br J Pharmacol. 2011;162(3):566–573.
   PubMed Web of Science ®Google Scholar
• van Hees HWH, Dekhuijzen PNR, Heunks LMA. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(1):41–47.
   PubMed Web of Science ®Google Scholar
• Doorduin J, Sinderby CA, Beck J, et al. The calcium sensitizer levosimendan improves human diaphragm function. Am J Respir Crit Care Med. 2012;185(1):90–95.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Shaw P, Leigh PN, et al. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2019;90(10):1165–1170.
   PubMed Web of Science ®Google Scholar
• Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019;10:1–11.
   Web of Science ®Google Scholar
• Kjældgaard AL, Pilely K, Olsen KS, et al. Amyotrophic lateral sclerosis: the complement and inflammatory hypothesis. MolImmunol. 2018;102:14–25.
   Google Scholar
• Mantovani S, Gordon R, Macmaw JK, et al. Elevation of the terminal complement activation products C5a andC5b-9 in ALS patient blood. J Neuroimmunol. 2014;276(1–2):213–218.
   PubMed Web of Science ®Google Scholar
• Parker SE, Hanton AM, Stefanou SN, et al. Revisiting the role of the innate immune complement system in ALS. Neurobiol Dis. 2019;127:223–232.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Oda K, Endo C, et al. Methylcobalamin (methyl-B12) promotes regeneration of motor nerve terminals degenerating in anterior gracile muscle of gracile axonal dystrophy (GAD) mutant mouse. Neurosci Lett. 1994;170(1):195–197.
   PubMed Web of Science ®Google Scholar
• Kaji R, Kodama M, Imamura A, et al. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double-blind controlled study. Muscle Nerve. 1998;21(12):1775–1778.
   PubMed Web of Science ®Google Scholar
• Kaji R, Imai T, Iwasaki Y, et al. Ultra-high-dose methylcobalamin inamyotrophic lateral sclerosis: a long-term phase II/III randomised controlledstudy. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):451–457.
   PubMed Web of Science ®Google Scholar
• Izumi Y, Oki R, Kuwabara S, et al. [JETALS: the Japanese early-stage trial ofhigh dose methylcobalamin for ALS]. Brain Nerve. 2019 Nov;71(11):1261–1269.
   PubMedGoogle Scholar
• Ludolph AC, Schuster J, Dorst J, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018;17(8):681–688.
   PubMed Web of Science ®Google Scholar
• Yang B, Jiang H, Wang F, et al. UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis. Neurol Sci. 2019;40(11):2293–2302.
   PubMed Web of Science ®Google Scholar
• Körner S, Kollewe K, Ilsemann J, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20(4):647–654.
   PubMed Web of Science ®Google Scholar
• Georges M, Attali V, Golmard JL, et al. Reduced survival in patients with ALS with upper airway obstructive events on non-invasive ventilation. J Neurol Neurosurg Psychiatry. 2016;87(10):1045–1050.
   PubMed Web of Science ®Google Scholar
• Moglia C, Calvo A, Canosa A, et al. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotrophic Lateral Scler Fronttemporal Degener. 2017;18(7–8):590– 597.
   PubMed Web of Science ®Google Scholar
• Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423–433.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Westeneng HJ, Nikolakopoulos S, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451-e460.
   PubMed Web of Science ®Google Scholar
• Saville B, Quintana M, Broglio K, et al. The ALS platform trial: design considerations and statistical efficiencies. Abstracts from the 29th international Symposium on ALS/MN. Amyotrophic Lateral Scler Fronttemporal Degener. 2019;20(sup1):1–99.
   Google Scholar
• Sudhop T, Brun NC, Riedel C, et al. Master protocols in clinical trials: a universal swiss army knife? Lancet Oncol. 2019 June;20(6):e336–e342.
   PubMed Web of Science ®Google Scholar